Craig-Hallum Maintains ISpecimen(ISPC.US) With Buy Rating
Craig-Hallum Maintains ISpecimen(ISPC.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Natera (NTRA) and ISpecimen (ISPC)
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and ISpecimen (ISPC)
EF Hutton Trims ISpecimen's Price Target to $4.25 From $5.50, Maintains Buy Rating
ISpecimen Analyst Ratings
EF Hutton Maintains Buy on ISpecimen, Lowers Price Target to $4.25
No Data
No Data